Recent Patent Reform Bills and Their Implications for Prescription Drugs
JAMA, Vol. 329(6), p. 459-460, Link to full text at JAMA: https://jamanetwork.com/journals/jama/fullarticle/2800700
Posted: 21 Mar 2023
Date Written: February 14, 2023
Abstract
This Viewpoint discusses 3 bills introduced recently in Congress that focus on patent eligibility, fraud, and quality and that have major implications for clinical medicine and pharmaceutical development.
Link to full text at JAMA: https://jamanetwork.com/journals/jama/fullarticle/2800700.
Keywords: pharmaceutical, FDA, patent, prescription drug, legislation
JEL Classification: K00, K10, K23,
Suggested Citation: Suggested Citation
Tu, Shine (Sean) and Nagar, Sarosh and Kesselheim, Aaron S., Recent Patent Reform Bills and Their Implications for Prescription Drugs (February 14, 2023). JAMA, Vol. 329(6), p. 459-460, Link to full text at JAMA: https://jamanetwork.com/journals/jama/fullarticle/2800700, WVU College of Law Research Paper No. 2023-005, Available at SSRN: https://ssrn.com/abstract=4390925
Feedback
Feedback to SSRN
If you need immediate assistance, call 877-SSRNHelp (877 777 6435) in the United States, or +1 212 448 2500 outside of the United States, 8:30AM to 6:00PM U.S. Eastern, Monday - Friday.